Tdam USA Inc. Sells 494 Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Tdam USA Inc. lowered its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 10.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,345 shares of the specialty pharmaceutical company’s stock after selling 494 shares during the period. Tdam USA Inc.’s holdings in Jazz Pharmaceuticals PLC were worth $676,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. OppenheimerFunds Inc. raised its stake in shares of Jazz Pharmaceuticals PLC by 54.1% in the first quarter. OppenheimerFunds Inc. now owns 150,840 shares of the specialty pharmaceutical company’s stock valued at $21,891,000 after buying an additional 52,960 shares during the last quarter. UBS Group AG raised its stake in shares of Jazz Pharmaceuticals PLC by 17.3% in the first quarter. UBS Group AG now owns 338,433 shares of the specialty pharmaceutical company’s stock valued at $49,116,000 after buying an additional 50,032 shares during the last quarter. HighTower Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $347,000. Somerset Trust Co raised its stake in shares of Jazz Pharmaceuticals PLC by 0.4% in the second quarter. Somerset Trust Co now owns 3,194 shares of the specialty pharmaceutical company’s stock valued at $497,000 after buying an additional 14 shares during the last quarter. Finally, Pinnacle Associates Ltd. purchased a new stake in shares of Jazz Pharmaceuticals PLC during the first quarter valued at $235,000. 86.43% of the stock is currently owned by institutional investors.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) opened at 142.90 on Thursday. The company has a market cap of $8.58 billion, a P/E ratio of 21.59 and a beta of 1.10. Jazz Pharmaceuticals PLC has a 12 month low of $95.80 and a 12 month high of $163.75. The firm has a 50-day moving average price of $155.68 and a 200 day moving average price of $146.56.
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 23.80%. The firm had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. During the same period last year, the business earned $2.67 EPS. The company’s revenue was up 3.5% compared to the same quarter last year. On average, equities analysts expect that Jazz Pharmaceuticals PLC will post $11.02 earnings per share for the current year.
Several analysts have recently weighed in on JAZZ shares. BidaskClub raised Jazz Pharmaceuticals PLC from a “sell” rating to a “hold” rating in a report on Saturday, June 10th. Cowen and Company reissued an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Royal Bank Of Canada set a $210.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a report on Tuesday, June 27th. Piper Jaffray Companies reissued an “overweight” rating and set a $182.00 price objective on shares of Jazz Pharmaceuticals PLC in a report on Wednesday, June 7th. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Thursday, April 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the company. Jazz Pharmaceuticals PLC presently has an average rating of “Buy” and a consensus target price of $182.96.
In related news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00. Following the completion of the transaction, the executive vice president now directly owns 22,223 shares of the company’s stock, valued at approximately $3,347,894.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Rick E. Winningham sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $150.00, for a total value of $750,000.00. Following the transaction, the director now directly owns 10,391 shares of the company’s stock, valued at $1,558,650. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,600 shares of company stock worth $1,641,720. 4.30% of the stock is currently owned by company insiders.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.